By Nana O 
A groundbreaking preclinical study from Weill Cornell Medicine researchers suggests that the intricate three-dimensional folding of DNA within the nucleus of brain cells could be a critical, previously overlooked factor in understanding and potentially treating glioblastoma, one of the most aggressive and devastating forms of brain cancer. Published on April 3 in the prestigious journal Molecular Cell, these findings propose a paradigm shift in cancer research, moving beyond a singular focus on genetic mutations to encompass the spatial organization and regulatory logic of genes within the cellular architecture. This novel perspective opens new avenues for identifying therapeutic targets and developing more effective treatment strategies for a disease that has long defied conventional approaches.
Glioblastoma, characterized by its rapid growth and infiltrative nature, has a notoriously poor prognosis, with median survival rates often measured in months, even with aggressive treatment. Despite decades of research into the genetic underpinnings of this malignancy, characterized by a complex landscape of mutations, amplifications, and rearrangements in oncogenes and tumor suppressor genes, effective treatments remain elusive. "Glioblastoma is one of the most aggressive and incurable tumors," stated Dr. Effie Apostolou, an associate professor of molecular biology in medicine at Weill Cornell and a co-lead investigator of the study. "Although we know a lot about the mutations and the genes that characterize it, we still have no effective ways to stop it. Now, we’re bringing a fresh perspective to the problem. We may have a chance of figuring out the regulatory logic of this cancer and identifying potential control centers that we can target to eliminate it."
The core of this new perspective lies in understanding how the vast amount of genetic material in the human genome – approximately six feet of DNA when stretched linearly – is meticulously packaged to fit within the minuscule nucleus of a cell, which is roughly 80 times smaller than a grain of sand. This remarkable feat of cellular engineering involves multiple layers of DNA folding, bringing physically distant regions of the genome into close proximity. It is within these three-dimensional arrangements, or "hubs," that the researchers have identified a critical mechanism influencing cancer development. "By examining the DNA organization in the 3D space, we uncovered hubs where multiple genetic regions that look like they should be disconnected are actually able to communicate and work together," Dr. Apostolou explained.
Uncovering 3D Gene Hubs in Glioblastoma
In healthy cells, these DNA hubs are thought to orchestrate normal physiological processes, such as embryonic development and cell differentiation, by coordinating the expression of genes that are spatially co-located. However, the Weill Cornell Medicine team’s analysis of glioblastoma cells from various patients revealed a starkly different scenario. They observed that in cancerous cells, these hubs were reconfigured, leading to the aberrant clustering of cancer-driving genes. More surprisingly, these oncogenic hubs also engaged in communication with other genes that had not previously been implicated in glioblastoma. This suggests that the three-dimensional architecture of the genome, rather than just the presence of specific mutations, plays a significant role in dictating the malignant behavior of these cells.
"This study shows that the 3D organization of DNA inside tumor cells plays a powerful role in driving brain cancer behavior — sometimes even more than mutations themselves," emphasized Dr. Howard Fine, the Louis and Gertrude Feil Professor of Medicine in Neurology at Weill Cornell Medicine and director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center, who co-led the research. This assertion is particularly significant, as the field of oncology has historically prioritized the identification and targeting of specific gene mutations, such as those found in the EGFR or PTEN pathways, which are frequently altered in glioblastoma.
The study’s co-first authors, Dr. Sarah Breves, a surgical resident at NewYork-Presbyterian/Weill Cornell Medical Center working in Dr. Apostolou’s lab, and Dr. Dafne Campigli Di Giammartino from the Instituto Italiano di Tecnologia in Genova, Italy, played pivotal roles in this discovery. Their meticulous work involved obtaining tumor samples from patients undergoing treatment at NewYork-Presbyterian/Weill Cornell Medical Center, with their informed consent, to analyze the DNA organization within their glioblastoma cells.
Form Dictating Function: Silencing the Hubs
The researchers hypothesized that these identified DNA hubs, particularly those containing suspected cancer-related genes, might be crucial for maintaining the malignant phenotype of glioblastoma cells. In healthy individuals, the DNA regions that coalesce into these cancer-associated hubs are typically "quiet," meaning the genes within them are not actively transcribed into proteins that drive abnormal cellular function. To test their hypothesis, the team employed a cutting-edge gene-editing tool, CRISPR interference (CRISPRi), to selectively silence a suspected cancer-related hub within glioblastoma cells cultured in vitro.
The results were dramatic and illuminating. Silencing the hub triggered a cascading effect, a "domino effect," as described by Dr. Apostolou. The activity of numerous genes connected within the silenced hub plummeted. Crucially, multiple genes known to promote cancer were disrupted, leading to a significant reduction in the cancer cells’ ability to form tumor-like spheres – a hallmark of aggressive tumor growth and self-renewal. "We were able to alter the oncogenic program of glioblastoma cells and their ability to organize and form something like cancer in the dish," Dr. Apostolou reported, underscoring the direct impact of spatial genome organization on cancer’s fundamental characteristics. This experiment provided compelling evidence that manipulating the three-dimensional arrangement of DNA could be a potent strategy for disrupting cancer’s progression.
A Broad Impact: Beyond Brain Cancer
The implications of these findings extend far beyond glioblastoma. Motivated by their discoveries in brain cancer, the Weill Cornell Medicine researchers expanded their investigation to analyze previously published genomic data from 16 different types of cancer. Their analysis revealed a striking pattern: these hyperconnected 3D gene hubs appear to be a common feature across a wide spectrum of malignancies, including melanoma, lung cancer, prostate cancer, uterine cancer, and many others. While each cancer type exhibited its own unique constellation of interconnected hubs, the researchers also identified shared hubs that were prevalent across multiple cancer types. This suggests that the aberrant spatial organization of DNA is not an isolated phenomenon but rather a fundamental aspect of tumorigenesis across diverse tissues.
A critical aspect of their investigation focused on the origins of these aberrant 3D hubs. Contrary to the prevailing focus on genetic mutations, the study found that the majority of these hubs were not a direct consequence of obvious DNA alterations such as breaks, amplifications, or rearrangements. Instead, their formation was frequently driven by epigenetic changes. Epigenetics refers to heritable changes in gene expression that occur without altering the underlying DNA sequence. These alterations can affect how DNA is packaged around proteins called histones and how regulatory machinery interacts with DNA, thereby influencing whether genes are turned on or off. The researchers observed that the protein complexes responsible for binding to specific DNA sequences and modulating gene activity played a significant role in the assembly of these 3D hubs. This highlights the intricate interplay between the genome’s linear sequence, its three-dimensional organization, and the epigenetic mechanisms that govern gene expression.
Future Directions and Therapeutic Potential
The identification of these key control hubs within the three-dimensional genome structure opens up exciting new possibilities for therapeutic intervention. "By identifying key control hubs in this 3D structure, we’ve uncovered new potential targets for future treatments," Dr. Fine stated. As the associate director for translational research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Dr. Fine is keenly focused on translating these basic science discoveries into clinical applications. "Next, we will explore how these hubs form and whether we can safely disrupt them to slow or stop tumor growth. Our research suggests that targeting the epigenetic and spatial genome organization could complement traditional molecular therapies."
This research represents a significant step forward in understanding the complex biology of cancer. By shifting the focus to the three-dimensional architecture of the genome, researchers are gaining a more holistic view of how genes are regulated and how disruptions in this regulation can lead to disease. The potential to target these spatial "control centers" offers a novel strategy that could overcome the limitations of current therapies, which often struggle with the immense genetic heterogeneity of tumors.
The timeline for translating these preclinical findings into clinical treatments is still a matter of ongoing research and development. However, the identification of these 3D hubs as potential therapeutic targets provides a clear and actionable path forward. Future research will likely involve developing sophisticated molecular tools to precisely target and disrupt these aberrant genomic structures. This could involve novel epigenetic modifiers, small molecules that interfere with the protein machinery that forms these hubs, or even advanced gene-editing techniques.
The broader implications of this study are profound. If these 3D gene hubs are indeed a common feature across many cancers, the therapeutic strategies developed to target them could have wide-ranging applications, potentially benefiting patients with a variety of malignancies. This paradigm shift from a purely mutational focus to an organizational and regulatory one underscores the dynamic and complex nature of cancer biology and offers renewed hope in the relentless pursuit of effective cancer cures. The Weill Cornell Medicine team’s work serves as a powerful reminder that understanding the intricate spatial organization of our genetic material is as crucial as understanding its linear sequence in the fight against disease.
